Pregnant women with rheumatoid arthritis face an increased risk for preterm birth and small for gestational age newborns, according to recent data.

Researchers evaluated the effects of biologic and targeted synthetic DMARDs on patient-reported outcomes in rheumatoid arthritis.

An executive order called for a reduction in childhood vaccines, prompting pushback from health care providers.

Continued low-dose glucocorticoid maintenance therapy in ANCA-associated vasculitis does not reduce major relapse risk but can increase damage accrual.

Updated CHEST guidelines offer 13 conditional recommendations for managing adult bronchiectasis and reducing exacerbation frequency ...

Despite a higher symptom burden, multimodal and multidisciplinary treatment is underutilized in older patients with chronic pain ...

Individuals with atopic dermatitis have an increased risk for herpes zoster — a risk that increases with atopic dermatitis severity.

Applying the 2025 GRAPPA and EULAR definitions in routine clinical practice can help identify patients with psoriatic arthritis who are at risk for persistent symptom burden and treatment-refractory ...

The first doses of mFLUSIVA are expected to be available for clinical use ahead of the 2026-2027 respiratory virus season. HealthDay News — The U.S. Food and Drug Administration (FDA) has approved the ...

Patients with chronic inflammatory diseases who undergo transcatheter aortic valve replacement face a higher risk for vascular complications but have comparable survival outcomes to those without ...

In the phase 3 IZAR-1 trial, 42.1% of biologic-naïve adults with active PsA achieved ACR50 at week 16 in the sonelokimab 60mg with induction arm. Topline data were announced from a phase 3 trial ...